Trofinetide
Phase 3Completed 0 watching 0 views this week๐ Rising
72
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Rett Syndrome
Conditions
Rett Syndrome
Trial Timeline
Jan 29, 2020 โ Aug 19, 2022
NCT ID
NCT04279314About Trofinetide
Trofinetide is a phase 3 stage product being developed by Acadia Pharmaceuticals for Rett Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT04279314. Target conditions include Rett Syndrome.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04988867 | Phase 2/3 | Terminated |
| NCT04776746 | Phase 3 | Terminated |
| NCT04279314 | Phase 3 | Completed |
| NCT04181723 | Phase 3 | Completed |
Competing Products
20 competing products in Rett Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Esomeprazole + Aspirin + Rofecoxib | AstraZeneca | Approved | 85 |
| Esomeprazole + Lansoprazole | AstraZeneca | Approved | 85 |
| Esomeprazole Magnesium | AstraZeneca | Approved | 85 |
| AZD5213 and placebo | AstraZeneca | Phase 2 | 52 |
| fingolimod (FTY720) | Novartis | Phase 1/2 | 41 |
| PF-03654746 + Placebo + Placebo + PF-03654746 | Pfizer | Phase 2 | 51 |
| Aripiprazole | Bristol Myers Squibb | Pre-clinical | 22 |
| NBI-98854 | Neurocrine Biosciences | Phase 2 | 49 |
| Valbenazine + Placebo oral capsule | Neurocrine Biosciences | Phase 2 | 49 |
| Valbenazine | Neurocrine Biosciences | Phase 2 | 49 |
| NBI-98854 | Neurocrine Biosciences | Phase 1 | 30 |
| Valbenazine + Placebo oral capsule | Neurocrine Biosciences | Phase 2 | 49 |
| NBI-98854 + Placebo | Neurocrine Biosciences | Phase 2 | 49 |
| Valbenazine | Neurocrine Biosciences | Phase 2 | 49 |
| NBI-98854 + Placebo | Neurocrine Biosciences | Phase 2 | 49 |
| Abobotulinum toxin A | Ipsen | Pre-clinical | 20 |
| GWP42003-P + Placebo | Jazz Pharmaceuticals | Phase 3 | 74 |
| GWP42003-P | Jazz Pharmaceuticals | Phase 3 | 74 |
| trofinetide | Acadia Pharmaceuticals | Phase 3 | 72 |
| Trofinetide | Acadia Pharmaceuticals | Phase 2/3 | 60 |